hydralazine has been researched along with Uterine Cervical Neoplasms in 10 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg/day and IV) 150 mg/day." | 2.71 | A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. ( Angeles, E; Cabrera, G; Cetina, L; Chanona-Vilchis, J; Chavez-Blanco, A; Duenas-González, A; Perez-Cardenas, E; Revilla-Vazquez, A; Sandoval, K; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Zambrano, P, 2005) |
| "Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner." | 1.38 | DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. ( Candelaria, M; Chavez-Blanco, A; de la Cruz-Hernandez, E; Diaz-Chavez, J; Dominguez, G; Duenas-Gonzalez, A; Gonzalez-Fierro, A; Perez-Cardenas, E; Soto-Reyes, E; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE, 2012) |
| "Hydralazine is a stable DNA methylation inhibitor that has minimal toxicity in vitro and in vivo." | 1.35 | Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. ( Song, Y; Zhang, C, 2009) |
| "In some cervical cancer cell lines, these drugs led to increased transcription of p53, and increased its stabilization due to acetylation at lysines 273 and 282, which allowed a higher bax-protein transactivating effect." | 1.34 | The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. ( Cantú, D; Contreras-Paredes, A; de la Cruz-Hernández, E; Dueñas-González, A; Lizano, M; Mohar, A; Pérez-Cárdenas, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mani, E | 1 |
| Medina, LA | 1 |
| Isaac-Olivé, K | 1 |
| Dueñas-González, A | 8 |
| Song, Y | 1 |
| Zhang, C | 1 |
| Candelaria, M | 3 |
| Cetina, L | 3 |
| Pérez-Cárdenas, E | 7 |
| de la Cruz-Hernández, E | 5 |
| González-Fierro, A | 4 |
| Trejo-Becerril, C | 6 |
| Taja-Chayeb, L | 6 |
| Chanona, J | 1 |
| Arias, D | 1 |
| Coronel, J | 1 |
| Pacheco, I | 1 |
| Arias-Bofill, D | 1 |
| Vidal, S | 2 |
| Perez-Plasencia, C | 1 |
| Chávez-Blanco, A | 3 |
| Gutiérrez, O | 1 |
| Dominguez, GI | 1 |
| Trujillo, JE | 2 |
| Soto-Reyes, E | 1 |
| Dominguez, G | 1 |
| Diaz-Chavez, J | 1 |
| Segura-Pacheco, B | 2 |
| Mariscal, I | 1 |
| Chavez, A | 1 |
| Acuña, C | 1 |
| Salazar, AM | 1 |
| Lizano, M | 2 |
| Zambrano, P | 1 |
| Revilla-Vazquez, A | 1 |
| Angeles, E | 1 |
| Cabrera, G | 1 |
| Sandoval, K | 1 |
| Chanona-Vilchis, J | 1 |
| Contreras-Paredes, A | 1 |
| Cantú, D | 1 |
| Mohar, A | 1 |
| Song, YH | 1 |
| Zhang, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for hydralazine and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Double-Blind | 2011 |
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.
Topics: 5-Methylcytosine; Adult; Aged; Binding Sites; Biopsy; Cardiovascular Diseases; Cohort Studies; Cytos | 2005 |
8 other studies available for hydralazine and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Methylation; DNA Modification Methyl | 2014 |
Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Topics: Adenomatous Polyposis Coli Protein; Antihypertensive Agents; Apoptosis; beta Catenin; Cell Line, Tum | 2009 |
Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brachytherapy; Cisplatin; Combined Modality Therapy; Epigenesis, | 2010 |
Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; DNA Methylation | 2011 |
DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Chrom | 2012 |
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Cycle; Cyclin-Dependen | 2003 |
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
Topics: Acetylation; Alphapapillomavirus; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA M | 2007 |
[Effect of Hydralazine on demethylation status and expression of APC gene, proliferation and apoptosis of human cervical cancer cell lines].
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor | 2007 |